XORTX Therapeutics XRTX Stock
XORTX Therapeutics Price Chart
XORTX Therapeutics XRTX Financial and Trading Overview
| XORTX Therapeutics stock price | 2.22 USD |
| Previous Close | 2.3 USD |
| Open | 2.23 USD |
| Bid | 1.61 USD x 200 |
| Ask | 2.88 USD x 200 |
| Day's Range | 2.13 - 2.3 USD |
| 52 Week Range | 1.73 - 7.05 USD |
| Volume | 17.09K USD |
| Avg. Volume | 1.23M USD |
| Market Cap | 3.84M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.45 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
XRTX Valuation Measures
| Enterprise Value | 2.86M USD |
| Trailing P/E | N/A |
| Forward P/E | 2.768683 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 7.4247494 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -1.191 |
Trading Information
XORTX Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -52.46% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 7.05 USD |
| 52 Week Low | 1.73 USD |
| 50-Day Moving Average | 2.4 USD |
| 200-Day Moving Average | 2.98 USD |
XRTX Share Statistics
| Avg. Volume (3 month) | 1.23M USD |
| Avg. Daily Volume (10-Days) | 35.14K USD |
| Shares Outstanding | 1.73M |
| Float | 1.37M |
| Short Ratio | 0.02 |
| % Held by Insiders | 8.25% |
| % Held by Institutions | 2.23% |
| Shares Short | 53.65K |
| Short % of Float | 3.54% |
| Short % of Shares Outstanding | 3.47% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:5 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -53.81% |
| Return on Equity (ttm) | -137.44% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -2398430 USD |
| Net Income Avi to Common (ttm) | -2766103 USD |
| Diluted EPS (ttm) | -2.45 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 250.28K USD |
| Total Cash Per Share (mrq) | 0.18 USD |
| Total Debt (mrq) | 15.06K USD |
| Total Debt/Equity (mrq) | 1.17 USD |
| Current Ratio (mrq) | 0.865 |
| Book Value Per Share (mrq) | 0.299 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -2626355 USD |
| Levered Free Cash Flow (ttm) | -1619871 USD |
Profile of XORTX Therapeutics
| Country | United States |
| State | AB |
| City | Calgary |
| Address | 3710 - 33rd Street NW |
| ZIP | T2L 2M1 |
| Phone | 403-455-7727 |
| Website | https://www.xortx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.
Q&A For XORTX Therapeutics Stock
What is a current XRTX stock price?
XORTX Therapeutics XRTX stock price today per share is 2.22 USD.
How to purchase XORTX Therapeutics stock?
You can buy XRTX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for XORTX Therapeutics?
The stock symbol or ticker of XORTX Therapeutics is XRTX.
Which industry does the XORTX Therapeutics company belong to?
The XORTX Therapeutics industry is Biotechnology.
How many shares does XORTX Therapeutics have in circulation?
The max supply of XORTX Therapeutics shares is 1.73M.
What is XORTX Therapeutics Price to Earnings Ratio (PE Ratio)?
XORTX Therapeutics PE Ratio is now.
What was XORTX Therapeutics earnings per share over the trailing 12 months (TTM)?
XORTX Therapeutics EPS is -2.45 USD over the trailing 12 months.
Which sector does the XORTX Therapeutics company belong to?
The XORTX Therapeutics sector is Healthcare.
XORTX Therapeutics XRTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
- {{ link.label }} {{link}}